ABVC Biopharma Inc

Company Profile

ABVC Biopharma Inc had its IPO on 2017-10-11 under the ticker symbol ABVC.

The company operates in the Healthcare sector and Biotechnology industry. ABVC Biopharma Inc has a staff strength of 28 employees.

Stock update

Shares of ABVC Biopharma Inc opened at $1.07 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.07 - $1.18, and closed at $1.13.

This is a +5.61% increase from the previous day's closing price.

A total volume of 21,548 shares were traded at the close of the day’s session.

In the last one week, shares of ABVC Biopharma Inc have slipped by -8.87%.

ABVC Biopharma Inc's Key Ratios

ABVC Biopharma Inc has a market cap of $21.53 million, indicating a price to book ratio of 4.08 and a price to sales ratio of 66.5973.

In the last 12-months ABVC Biopharma Inc’s revenue was $342996 with a gross profit of $350711 and an EBITDA of $-18407944. The EBITDA ratio measures ABVC Biopharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ABVC Biopharma Inc’s operating margin was -5372.83% while its return on assets stood at -100.88% with a return of equity of -281.76%.

In Q3, ABVC Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 57.3%.

ABVC Biopharma Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ABVC Biopharma Inc’s profitability.

ABVC Biopharma Inc stock is trading at a EV to sales ratio of 75.3857 and a EV to EBITDA ratio of -1.46. Its price to sales ratio in the trailing 12-months stood at 66.5973.

ABVC Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$10.48 million

Total Liabilities

$3.89 million

Operating Cash Flow

$-1523150.00

Capital Expenditure

$4357

Dividend Payout Ratio

0%

ABVC Biopharma Inc ended 2024 with $10.48 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.48 million while shareholder equity stood at $5.92 million.

ABVC Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $3.89 million in other current liabilities, 32632.00 in common stock, $-50040501.00 in retained earnings and $0.00 in goodwill. Its cash balance stood at $1.32 million and cash and short-term investments were $1.40 million. The company’s total short-term debt was $2,230,002 while long-term debt stood at $0.

ABVC Biopharma Inc’s total current assets stands at $2.90 million while long-term investments were $816160.00 and short-term investments were $77583.00. Its net receivables were $547680.00 compared to accounts payable of $0 and inventory worth $20489.00.

In 2024, ABVC Biopharma Inc's operating cash flow was $-1523150.00 while its capital expenditure stood at $4357.

Comparatively, ABVC Biopharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.13

52-Week High

$3.13

52-Week Low

$0.5

Analyst Target Price

$2.02

ABVC Biopharma Inc stock is currently trading at $1.13 per share. It touched a 52-week high of $3.13 and a 52-week low of $3.13. Analysts tracking the stock have a 12-month average target price of $2.02.

Its 50-day moving average was $2.78 and 200-day moving average was $5.89 The short ratio stood at 1.4 indicating a short percent outstanding of 0%.

Around 4002.6% of the company’s stock are held by insiders while 184.1% are held by institutions.